Brian M Olson
Overview
Explore the profile of Brian M Olson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
743
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Olson B, Chaudagar K, Bao R, Saha S, Hong C, Li M, et al.
Mol Cancer Ther
. 2023 Apr;
22(6):751-764.
PMID: 37014264
Non-T-cell-inflamed immunologically "cold" tumor microenvironments (TME) are associated with poor responsiveness to immune checkpoint blockade (ICB) and can be sculpted by tumor cell genomics. Here, we evaluated how retinoblastoma (Rb)...
2.
Ruggieri A, Yarchoan M, Goyal S, Liu Y, Sharon E, Chen H, et al.
Clin Cancer Res
. 2022 Jul;
28(19):4336-4345.
PMID: 35833954
Purpose: Biliary tract cancers (BTC) are aggressive malignancies refractory to chemotherapy and immunotherapy. MEK inhibition (MEKi)-based regimens may have utility in this disease when combined with PD-L1 blockade. We hypothesize...
3.
Morel K, Sheahan A, Burkhart D, Baca S, Boufaied N, Liu Y, et al.
Nat Cancer
. 2021 Apr;
2(4):444-456.
PMID: 33899001
Prostate cancers are considered to be immunologically 'cold' tumors given the very few patients who respond to checkpoint inhibitor (CPI) therapy. Recently, enrichment of interferon-stimulated genes (ISGs) predicted a favorable...
4.
Zhang Y, Ware M, Zaidi M, Ruggieri A, Olson B, Komar H, et al.
Mol Cancer Ther
. 2020 Oct;
20(1):150-160.
PMID: 33037138
Pancreatic ductal adenocarcinoma (PDAC) has a prominent fibrotic stroma, which is a result of interactions between tumor, immune and pancreatic stellate cells (PSC), or cancer-associated fibroblasts (CAF). Targeting inflammatory pathways...
5.
Sullivan J, AlAdra D, Olson B, McNeel D, Burlingham W
Front Immunol
. 2020 Sep;
11:1867.
PMID: 32983104
Originally identified as lymphocyte regulation of fellow lymphocytes, our understanding of infectious tolerance has undergone significant evolutions in understanding since being proposed in the early 1970s by Gershon and Kondo...
6.
Kyriakopoulos C, Eickhoff J, Ferrari A, Schweizer M, Wargowski E, Olson B, et al.
Clin Cancer Res
. 2020 Jun;
26(19):5162-5171.
PMID: 32513836
Purpose: Preclinical studies demonstrated that a DNA vaccine (pTVG-AR, MVI-118) encoding the androgen receptor ligand-binding domain (AR LBD) augmented antigen-specific CD8 T cells, delayed prostate cancer progression and emergence of...
7.
Olson B, Gamat M, Seliski J, Sawicki T, Jeffery J, Ellis L, et al.
Cancer Immunol Res
. 2017 Oct;
5(12):1074-1085.
PMID: 29051161
Androgen deprivation is the primary therapy for recurrent prostate cancer, and agents targeting the androgen receptor (AR) pathway continue to be developed. Because androgen-deprivation therapy (ADT) has immmunostimulatory effects as...
8.
Johnson L, Olson B, McNeel D
J Immunother Cancer
. 2017 Jul;
5(1):56.
PMID: 28716080
Background: Immunotherapies have demonstrated clinical benefit for many types of cancers, however many patients do not respond, and treatment-related adverse effects can be severe. Hence many efforts are underway to...
9.
Patnaik A, Swanson K, Csizmadia E, Solanki A, Landon-Brace N, Gehring M, et al.
Cancer Discov
. 2017 Mar;
7(7):750-765.
PMID: 28274958
Several kinase inhibitors that target aberrant signaling pathways in tumor cells have been deployed in cancer therapy. However, their impact on the tumor immune microenvironment remains poorly understood. The tyrosine...
10.
Olson B, Bradley E, Sawicki T, Zhong W, Ranheim E, Bloom J, et al.
Prostate
. 2017 Feb;
77(7):812-821.
PMID: 28181678
Background: The androgen receptor (AR) is a key oncogenic driver of prostate cancer, and has been the primary focus of prostate cancer treatment for several decades. We have previously demonstrated...